Compare · DXCM vs TNDM
DXCM vs TNDM
Side-by-side comparison of DexCom Inc. (DXCM) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 22.7x TNDM ($1.24B).
- Over the past year, DXCM is down 16.2% and TNDM is down 12.6% - TNDM leads by 3.6 points.
- Both names hit the wire about 30 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Tandem Diabetes Care Inc.
- Price
- $72.74-0.92%
- $18.02-3.09%
- Market cap
- $28.08B
- $1.24B
- 1M return
- +21.17%
- -9.31%
- 1Y return
- -16.20%
- -12.57%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2013
- News (4w)
- 30
- 30
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
Latest TNDM
- SEC Form 4 filed by PRESIDENT & CEO Sheridan John F
- SEC Form 4 filed by EVP, Chief Strategy Officer Gasser Elizabeth Anne
- SEC Form 4 filed by EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh
- SEC Form 4 filed by EVP & Chief Operating Officer Kyrillos Jean-Claude
- SEC Form 4 filed by EVP & Chief Legal Officer Hansen Shannon Marie
- SEC Form 4 filed by EVP & Chief Admin. Officer Morrison Susan
- SEC Form 4 filed by EVP & Chief Technology Officer Carpenter Rick
- Tandem Diabetes Care upgraded by Wells Fargo with a new price target
- SEC Form SD filed by Tandem Diabetes Care Inc.
- SEC Form S-8 filed by Tandem Diabetes Care Inc.